

Reprinted from The Lancet, Vol 390, Prince HM, et al., Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. pp. 555–66. Copyright © (2017), with permission from Elsevier. https://www.thelancet.com/journals/lancet/home.